Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients.
暂无分享,去创建一个
L. V. Van Gaal | F. Cools | M. D. de Broe | G. Verpooten | R. Claes | M. Broe | M. G. Van der Planken | L. Bedert | M. Planken | M. De broe | M. de Broe | L. V. Gaal | Rita Claes
[1] M. Robertson,et al. Oxidation of low density lipoproteins from patients with renal failure or renal transplants. , 1995, Kidney international.
[2] R. Chalmers,et al. Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. , 1995, QJM : monthly journal of the Association of Physicians.
[3] I. Godsland,et al. Insulin resistance, lipoproteins, body fat and hemostasis in nonobese men with angina and a normal or abnormal coronary angiogram. , 1994, Journal of the American College of Cardiology.
[4] E. Vilella,et al. Low-density lipoprotein metabolism in rats treated with cyclosporine. , 1993, Metabolism: clinical and experimental.
[5] E. Tremoli,et al. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[6] M. Seed,et al. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? , 1993, The Lancet.
[7] D. Hricik,et al. THE EFFECTS OF STEROID WITHDRAWAL ON THE LIPOPROTEIN PROFILES OF CYCLOSPORINE‐TREATED KIDNEY AND KIDNEY‐PANCREAS TRANSPLANT RECIPIENTS , 1992, Transplantation.
[8] J. Sambrook,et al. Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] J. Simons,et al. Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. , 1992, Australian and New Zealand journal of medicine.
[10] D. Raccah,et al. Hemobiology, vascular disease, and diabetes with special reference to impaired fibrinolysis. , 1992, Metabolism: clinical and experimental.
[11] R. Nachman. Review: Stratton Lecture. Thrombosis and atherogenesis: molecular connections. , 1992, Blood.
[12] D. Wilcken,et al. Decreases in apolipoprotein(a) after renal transplantation: implications for lipoprotein(a) metabolism. , 1992, Clinical chemistry.
[13] B. Lacour,et al. Atherosclerosis and lipid disorders after renal transplantation. , 1991, Kidney international. Supplement.
[14] L. Romics,et al. Lp(a) lipoprotein concentration in serum of patients with heavy proteinuria of different origin. , 1989, Clinical chemistry.
[15] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[16] P. Vague,et al. Relationships between plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. , 1987, Diabete & metabolisme.
[17] J. Fruchart,et al. Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. , 1987, Clinical chemistry.
[18] J. Chapman,et al. Increased plasma LDL cholesterol after renal transplantation associated with cyclosporine immunosuppression. , 1987, Transplantation proceedings.
[19] W. Kannel. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. , 1985, American heart journal.
[20] A. Sanghvi,et al. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients. , 1985, Transplantation proceedings.
[21] T. Lerut,et al. THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTS , 1985, The Lancet.
[22] D. Morel,et al. Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.
[23] S P Azen,et al. OBTAINING CONFIDENCE INTERVALS FOR THE RISK RATIO IN COHORT STUDIES , 1978 .
[24] L. Mannucci,et al. Hypertriglyceridemia and regulation of fibrinolytic activity. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[25] H. Cohen,et al. Evidence for chronic platelet hyperaggregability and in vivo activation in cyclosporin-treated renal allograft recipients. , 1988, Thrombosis research.
[26] A. Gotto,et al. CORONARY ARTERY DISEASE Association of levels of lipoprotein Lp ( a ) , plasma lipids , and other lipoproteins with coronary artery disease documented by angiography , 2022 .